Cargando…
Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial
INTRODUCTION: The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy. METHODS: The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moderate-severe hospitalized patients with confirmed...
Autores principales: | Alavi Darazam, Ilad, Shokouhi, Shervin, Mardani, Masoud, Pourhoseingholi, Mohamad Amin, Rabiei, Mohammad Mahdi, Hatami, Firouze, Shabani, Minoosh, Moradi, Omid, Gharehbagh, Farid Javandoust, Irvani, Seyed Sina Naghibi, Amirdosara, Mahdi, Hajiesmaeili, Mohammadreza, Rezaei, Omidvar, Khoshkar, Ali, Lotfollahi, Legha, Gachkar, Latif, Dehbsneh, Hadiseh Shabanpour, Khalili, Negar, Soleymaninia, Azam, Kusha, Akram Hoseyni, Shoushtari, Maryam Taleb, Torabinavid, Parham |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8270750/ https://www.ncbi.nlm.nih.gov/pubmed/34273635 http://dx.doi.org/10.1016/j.intimp.2021.107969 |
Ejemplares similares
-
Clinical and Epidemiological Characteristics of Coronavirus Disease 2019 in Iran: a Hospital-Based Observational Study
por: Darazam, Ilad Alavi, et al.
Publicado: (2021) -
Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021) -
An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a in severe COVID-19: The COVIFERON II randomized controlled trial
por: Alavi Darazam, Ilad, et al.
Publicado: (2021) -
Garcin syndrome in a case of acquired immunodeficiency syndrome
por: Darazam, Ilad Alavi, et al.
Publicado: (2022) -
One‐step and sequential SARSCOV‐2 polymerase chain reaction tests would not work every time
por: Hatami, Firouze, et al.
Publicado: (2022)